ArticleAdvanced healthcare materials2026
Tomographic Printing in a Chip: A Versatile Platform for Biomimetic 3D Organ-on-Chip.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Organ-on-chip (OoC) platforms are increasingly adopted for predictive in vitro testing. However, most remain limited by soft-lithography-derived 2.5D microfluidic architectures and nonphysiological rigid materials, or bioprinting approaches that require complex and failure-prone post-fabrication assembly. Here, we present a versatile approach that integrates tomographic volumetric additive manufacturing (TVAM) directly within preassembled microfluidic chips, enabling rapid, contactless fabrication of freeform 3D OoCs. Leveraging our open-source optical simulation framework, Dr.TVAM, we perform TVAM in custom-designed chips, eliminating post-printing manual assembly steps that commonly lead to leakage, contamination, and poor reproducibility. This strategy, termed TVAM-in-a-chip, supports the generation of diverse 3D channel architectures in multiple biocompatible photoresins spanning a wide range of chemistries and mechanical properties, including cell-laden formulations. We demonstrate multi-channel designs, compatibility with confocal imaging, and dynamic culture of epithelial and endothelial models. Overall, TVAM-in-a-chip overcomes key limitations of current OoC technologies and paves the way for a new generation of scalable, biomimetic 3D platforms for advanced in vitro modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.